Atypical chronic lymphocytic lymphoma (CLL) with CCND1 translocation is poorly described, particularly in the era of modern inhibitors of the B-cell receptor pathway. We present a patient with atypical CLL who had a significant response to ibrutinib, highlighting the effectiveness of this agent in higher risk CLL subgroups.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250984 | PMC |
| http://dx.doi.org/10.1002/ccr3.2773 | DOI Listing |
Publication Analysis
Top Keywords
atypical chronic
8
chronic lymphocytic
8
management atypical
4
lymphocytic leukemia
4
leukemia presenting
4
presenting extreme
4
extreme leukocytosis
4
leukocytosis atypical
4
lymphocytic lymphoma
4
lymphoma cll
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!